human growth hormone raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-13. Anything still debated is marked as such rather than presented as settled.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
== Interactions == Concomitant use of methenamine and sulfonamides can result in insoluble methenamine salts precipitating in urine and hence is not recommended. Urinary alkalinizing agents, such as antacids, carbonic anhydrase inhibitors, and certain foods, may diminish the effectiveness of methenamine by making the urine more alkaline and thereby preventing the hydrolysis of methenamine into formaldehyde. Conversely, urinary acidifying agents, like ascorbic acid (vitamin C), sodium acid phosphate, and ammonium chloride, may enhance the effectiveness of methenamine by making the urine more acidic and thereby facilitating its hydrolysis into formaldehyde. Formaldehyde has been found in vitro to react with hydrochloric acid to form the highly carcinogenic compound bis(chloromethyl) ether and it may be conceivable that this might likewise occur in the stomach.
{\displaystyle \mathbf {V} (f_{n},\tau _{n})={\begin{bmatrix}cos(\tau _{n}{\sqrt {f_{n})}}&1/{\sqrt {f_{n}}}sin(\tau _{n}{\sqrt {f_{n}}}\\-{\sqrt {f_{n}}}sin(\tau _{n}{\sqrt {f_{n}}})&cos(\tau _{n}{\sqrt {f_{n}}})\end{bmatrix}}\qquad f_{n}>0\qquad \qquad \qquad (3a)}
On the review aggregation website Metacritic, Half-Life has a score of 96 out of 100, indicating "universal acclaim". Computer Gaming World's Jeff Green said it was "not just one of the best games of the year. It's one of the best games of any year, an instant classic that is miles better than any of its immediate competition, and—in its single-player form—is the best shooter since the original Doom." Next Generation wrote: "It is fast paced, it is dramatic, and it brings the very idea of adventure on a PC out of the dark ages and into a 3D world. All that and not a single Orc in sight." IGN described it as "a tour de force in game design, the definitive single player game in a first-person shooter". GameSpot said it was the "closest thing to a revolutionary step the genre has ever taken". Several reviewers cited the level of immersion and interactivity as revolutionary. AllGame said, "It isn't everyday that you come across a game that totally revolutionizes an entire genre, but Half-Life has done just that." Hot Games commented on the realism, and how the environment "all adds up to a totally immersive gaming experience that makes everything else look quite shoddy in comparison". Gamers Depot wrote that it was the most immersive game they had played. The final portion of the game, taking place in the alien world of Xen, was generally considered the weakest. Besides introducing a wholly new and alien setting, it also featured a number of low-gravity jumping puzzles.
Sources: en.wikipedia.org
=== Hunger === Because patients are being fed intravenously, the subject does not physically eat, resulting in intense hunger pangs (pains). The brain uses signals from the mouth (taste and smell), the stomach and gastrointestinal tract (fullness) and blood (nutrient levels) to determine conscious feelings of hunger. In cases of TPN, the taste, smell and physical fullness requirements are not met, and so the patient experiences hunger, although the body is being fully nourished. Patients who eat food despite the inability can experience a wide range of complications, such as refeeding syndrome.
10 January – First Minister Humza Yousaf confirms those in Scotland convicted because of the Post Office scandal will be cleared following a similar announcement at Westminster for England and Wales, and that he will work with the UK government to bring this about. It is reported that David Page, the deputy chief officer at Police Scotland and the force's most senior member of civilian staff, has made a complaint against new Chief Constable Jo Farrell, doing so within weeks of her arrival. 11 January – First Minister Humza Yousaf confirms that the Scottish Government will "in essence replicate" the law in England and Wales banning unlicensed ownership of American XL bully dogs. Plans are announced for West Town, a £2bn 7,000 home development on land near Edinburgh Airport. 13 January – A 70-year-old woman is charged after a car ran into protesters at a pro-Palestine march in Edinburgh. 14 January – Ramsay El-Nakla, the brother-in-law of Humza Yousaf, has been charged by police in connection with drugs offences. 15 January – Robert O'Brien and Andrew Kelly are sentenced to life imprisonment with minimum terms of 22 and 18 years respectively for the 1996 murder of Caroline Glachan. James Stockan announces he will step down from the post of leader of Orkney Islands Council, as well as relinquishing his council seat, after six years in the role. 16 January – A yellow weather warning is in place for snow and ice for the whole of Scotland.
== Principle == Delayed neutrons are associated with the beta decay of the fission products. After prompt fission neutron emission the residual fragments are still neutron rich and undergo a beta decay chain. The more neutron rich the fragment, the more energetic and faster the beta decay. In some cases the available energy in the beta decay is high enough to leave the residual nucleus in such a highly excited state that neutron emission instead of gamma emission occurs. Using U-235 as an example, this nucleus absorbs thermal neutrons, and the immediate mass products of a fission event are two large fission fragments, which are remnants of the formed U-236 nucleus. These fragments emit two to three free neutrons (2.43 on average), called "prompt" neutrons. A subsequent fission fragment occasionally undergoes a stage of radioactive decay (which is a beta minus decay) that yields a new nucleus (the emitter nucleus) in an excited state that emits an additional neutron, called a "delayed" neutron, to get to ground state. These neutron-emitting fission fragments are called delayed neutron precursor atoms. The longest-lived groups can be traced to specific decay chains. In about 70% of 87Br beta decays (half-life 55 s), the 87Kr daughter is left in a nuclear state above the 5.4 MeV needed to eject its last neutron; it promptly releases a neutron, ending as stable 86Kr. The neutron emission rate is set by the rate of formation of 87Kr, so the group carries the 55 s half-life of the precursor.
=== (1) Venom collection methods === Venom milking is the most simplistic way of collecting a venom sample. It usually involves a vertebrate animal (Typically a snake) to deliver a venomous bite into a container. Similarly, electrical stimulation can be used for invertebrate animal (Insects and arachnids) subjects. This practice has allowed for the discovery of the basic properties of venom and to understand the biological factors involved in venom production such as venom regeneration periods. Other methods involve post-mortem dissection of the venom glands to collect the required materials (Venom or tissue).
Sources: en.wikipedia.org
=== Film === The rotoscoped film A Scanner Darkly was authorized by Dick's estate. It was released in July 2006 and stars Keanu Reeves as Fred/Bob Arctor and Winona Ryder as Donna. Rory Cochrane, Robert Downey Jr., and Woody Harrelson co-star as Arctor's drugged-out housemates and friends. The film was directed by Richard Linklater.
Throughout the 1970s, researchers explored two methods for automating the differential count: digital image processing and flow cytometry. Using technology developed in the 1950s and 60s to automate the reading of Pap smears, several models of image processing analyzers were produced. These instruments would scan a stained blood smear to find cell nuclei, then take a higher resolution snapshot of the cell to analyze it through densitometry. They were expensive, slow, and did little to reduce workload in the laboratory because they still required blood smears to be prepared and stained, so flow cytometry-based systems became more popular, and by 1990, no digital image analyzers were commercially available in the United States or western Europe. These techniques enjoyed a resurgence in the 2000s with the introduction of more advanced image analysis platforms using artificial neural networks. Early flow cytometry devices shot beams of light at cells in specific wavelengths and measured the resulting absorbance, fluorescence or light scatter, collecting information about the cells' features and allowing cellular contents such as DNA to be quantified. One such instrument—the Rapid Cell Spectrophotometer, developed by Louis Kamentsky in 1965 to automate cervical cytology—could generate blood cell scattergrams using cytochemical staining techniques. Leonard Ornstein, who had helped to develop the staining system on the Rapid Cell Spectrophotometer, and his colleagues later created the first commercial flow cytometric white blood cell differential analyzer, the Hemalog D.
== Research == Some related pyrrylphenylethanones had analgesic activity comparable to morphine. Some pyrrole analogues were reported to have analgesic effects comparable to lefetamine and being devoid of neurotoxic properties.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.